News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
277,105 Results
Type
Article (14885)
Company Profile (282)
Press Release (261938)
Section
Business (82234)
Career Advice (159)
Deals (13818)
Drug Delivery (35)
Drug Development (53693)
Employer Resources (33)
FDA (6209)
Job Trends (5333)
News (151494)
Policy (10979)
Tag
Academia (923)
Alliances (22157)
Alzheimer's disease (811)
Antibody-drug conjugate (ADC) (78)
Approvals (6212)
Artificial intelligence (98)
Bankruptcy (107)
Best Places to Work (4726)
Biotechnology (232)
Breast cancer (132)
Cancer (1201)
Cardiovascular disease (94)
Career advice (138)
CAR-T (102)
Cell therapy (299)
Clinical research (43472)
Collaboration (458)
Compensation (188)
COVID-19 (1039)
C-suite (126)
Cystic fibrosis (80)
Data (1230)
Diabetes (113)
Diagnostics (1304)
Earnings (30766)
Events (49858)
Executive appointments (375)
FDA (6781)
Funding (432)
Gene editing (80)
Gene therapy (215)
GLP-1 (350)
Government (1183)
Healthcare (6860)
Infectious disease (1093)
Inflammatory bowel disease (106)
IPO (7594)
Job creations (913)
Job search strategy (133)
Layoffs (204)
Legal (1473)
Lung cancer (171)
Lymphoma (84)
Manufacturing (108)
Medical device (2622)
Medtech (2623)
Mergers & acquisitions (6465)
Metabolic disorders (338)
Neuroscience (1150)
NextGen: Class of 2025 (2148)
Non-profit (899)
Northern California (1409)
Obesity (174)
Opinion (102)
Parkinson's disease (93)
Patents (96)
People (25998)
Phase I (15106)
Phase II (20287)
Phase III (12990)
Pipeline (577)
Postmarket research (888)
Preclinical (6160)
Radiopharmaceuticals (210)
Rare diseases (269)
Real estate (1484)
Regulatory (9286)
Research institute (967)
Series A (82)
Southern California (1258)
Startups (2001)
United States (11268)
Vaccines (198)
Weight loss (98)
Date
Today (37)
Last 7 days (500)
Last 30 days (1602)
Last 365 days (21028)
2025 (3244)
2024 (21254)
2023 (23225)
2022 (27886)
2021 (28886)
2020 (24508)
2019 (17050)
2018 (12430)
2017 (14721)
2016 (12645)
2015 (15324)
2014 (11032)
2013 (7936)
2012 (7892)
2011 (7947)
2010 (7714)
Location
Africa (154)
Asia (17922)
Australia (2979)
California (3217)
Canada (1000)
China (288)
Colorado (120)
Connecticut (135)
Europe (39397)
Florida (395)
Georgia (94)
Illinois (203)
Indiana (81)
Maryland (426)
Massachusetts (2599)
Minnesota (125)
New Jersey (826)
New York (888)
North Carolina (493)
Northern California (1409)
Ohio (100)
Pennsylvania (614)
South America (219)
Southern California (1258)
Texas (370)
Washington State (299)
277,105 Results for "jupiter orphan therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
February 5, 2025
·
5 min read
Press Releases
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
January 30, 2025
·
4 min read
Press Releases
Elixirgen Therapeutics Granted FDA Orphan Drug Designation for EXG-34217 for Treatment of Telomere Biology Disorders
February 21, 2025
·
2 min read
Press Releases
Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials
January 14, 2025
·
6 min read
Press Releases
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial
February 3, 2025
·
5 min read
Press Releases
Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
December 4, 2024
·
3 min read
Press Releases
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
January 7, 2025
·
6 min read
Press Releases
FDA Grants Orphan Drug Designation to Revolutionary Cystic Fibrosis Therapy
February 26, 2025
·
3 min read
Press Releases
Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq
December 3, 2024
·
4 min read
Biotech Bay
ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia
ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for RCT1100 for the treatment of primary ciliary dyskinesia (PCD).
June 27, 2024
·
4 min read
1 of 27,711
Next
